STAAR Surgical is trading 6.8% down at $24.64 as investors continue to react to disappointing profit metrics in its recent Q2 update.
- While Q2 revenue growth was strong, preliminary sales of over $90 million merely matched Street expectations and highlighted underlying regional weakness.
- The current decline reflects an ongoing repricing of the stock following the earnings report rather than fresh company-specific news.